Dave Inc. (DAVE) closed the last trading session at $192.33, gaining 12.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $300.11 indicates a 56% upside potential.The mean estimate comprises nine short-term price targets with a standard deviation of $31.79. While the lowest estimate of $250.00 indicates a 30% increase from the current price level, the most optimistic analyst expec ...

Core Viewpoint - KalVista Pharmaceuticals, Inc. (KALV) shows significant upside potential with a mean price target of $33.78, indicating an 117.1% increase from its current trading price of $15.56 [1] Price Targets and Analyst Estimates - The mean estimate consists of nine short-term price targets with a standard deviation of $5.4, where the lowest estimate is $22.00 (41.4% increase) and the highest is $39.00 (150.6% increase) [2] - A low standard deviation suggests strong agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about KALV's earnings prospects, as indicated by a positive trend in earnings estimate revisions [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 29.2%, with two estimates moving higher and no negative revisions [12] - KALV holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Movement - While the consensus price target may not be a reliable indicator of the stock's potential gain, the implied direction of price movement appears to be a useful guide [14]

Group 1 - Nomad Foods (NOMD) closed at $12.92, with a 6.8% gain over the past four weeks, and analysts set a mean price target of $16.83, indicating a 30.3% upside potential [1] - The mean estimate includes six short-term price targets with a standard deviation of $1.47, where the lowest estimate is $15.00 (16.1% increase) and the highest is $18.00 (39.3% increase) [2] - Analysts show strong agreement on the company's ability to report better earnings, with a positive trend in earnings estimate revisions correlating with potential stock upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 1.5% over the last 30 days, with one estimate moving higher and no negative revisions [12] - NOMD holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of potential gains, it does provide a directional guide for price movement [14]

Core Viewpoint - Hinge Health Inc. (HNGE) shows potential for significant upside, with a mean price target of $58.25 indicating a 39% increase from its current price of $41.92 [1] Price Targets and Analyst Estimates - The mean estimate consists of 16 short-term price targets, with a standard deviation of $6.92, indicating variability among analysts [2] - The lowest estimate is $48.00, suggesting a 14.5% increase, while the highest estimate is $72.00, indicating a potential surge of 71.8% [2] - A low standard deviation signifies strong agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Agreement - Analysts have shown increasing optimism about HNGE's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher [11] - The Zacks Consensus Estimate for the current year has risen by 63.2% over the past month, with four estimates increasing and no negative revisions [12] - HNGE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on price targets for investment decisions may not be prudent, as analysts' ability to set accurate targets has been questioned [3][10] - Price targets can be influenced by business incentives, leading to potentially inflated estimates [8]

Core Viewpoint - LiveOne (LVO) has shown a significant price increase of 21.5% over the past four weeks, with a mean price target of $11.5 indicating a potential upside of 121.2% from its current price of $5.2 [1] Price Targets and Analyst Consensus - The average price target for LVO ranges from a low of $10.00 to a high of $14.00, with a standard deviation of $1.91, suggesting a high degree of agreement among analysts [2] - The lowest estimate indicates a potential increase of 92.3%, while the most optimistic estimate points to a 169.2% upside [2] - A low standard deviation indicates that analysts have a strong consensus on the stock's price movement direction, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding LVO's earnings prospects, as evidenced by a positive trend in earnings estimate revisions [11] - Over the last 30 days, two earnings estimates have been revised higher, leading to a 10.2% increase in the Zacks Consensus Estimate for the current year [12] - LVO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Caution on Price Targets - While price targets are often sought after by investors, they can be misleading and should not be the sole basis for investment decisions [3][7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - Karyopharm Therapeutics (KPTI) has shown a significant price increase of 58% over the past four weeks, with a mean price target of $14.67 indicating a potential upside of 56.1% from the current price of $9.4 [1] Price Targets and Analyst Estimates - The mean estimate consists of six short-term price targets with a standard deviation of $5.32, where the lowest estimate is $6.00 (indicating a 36.2% decline) and the highest is $21.00 (indicating a 123.4% increase) [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about KPTI's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price movements [11] - Over the last 30 days, two estimates have been revised upward, leading to a 13.3% increase in the Zacks Consensus Estimate for the current year [12] Zacks Rank and Investment Potential - KPTI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential for upside in the near term [13] - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does suggest a positive direction for price movement [14]

Core Viewpoint - Deluxe (DLX) shares have increased by 6.3% recently, closing at $25.88, with a potential upside of 26.2% based on Wall Street analysts' mean price target of $32.67 [1] Price Targets and Analyst Estimates - The mean estimate includes three short-term price targets with a standard deviation of $2.08, indicating variability among analysts; the lowest estimate is $31.00 (19.8% increase), while the highest is $35.00 (35.2% increase) [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about DLX's earnings prospects, with a strong consensus on higher EPS estimates, which historically correlates with stock price movements [11] - Over the past 30 days, the Zacks Consensus Estimate for the current year has risen by 10.5%, with two estimates moving higher and no negative revisions [12] - DLX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13] Conclusion on Price Targets - While the consensus price target may not be a reliable measure of potential gains, the implied direction of price movement appears to be a useful guide for investors [14]

Group 1 - Central Garden (CENTA) shares have increased by 11.9% over the past four weeks, closing at $33.49, with a mean price target of $46 indicating a potential upside of 37.4% [1] - The average price targets range from a low of $33.00 to a high of $51.00, with a standard deviation of $8.68, suggesting variability in analyst estimates [2] - Analysts show strong agreement in revising earnings estimates higher, with two estimates moving up in the last 30 days and the Zacks Consensus Estimate increasing by 2.5% [12][11] Group 2 - The Zacks Rank for CENTA is 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of the stock's potential gain, it does provide a directional guide for price movement [14]

Core Viewpoint - Harmony Biosciences Holdings, Inc. (HRMY) shows potential for upside based on Wall Street analysts' short-term price targets, with a mean target of $46.45 indicating a 27% upside from the current price of $36.59 [1] Price Targets and Estimates - The mean estimate consists of 11 short-term price targets with a standard deviation of $8.02, indicating variability among analysts; the lowest estimate is $32.00 (12.5% decline), while the highest is $62.00 (69.5% increase) [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates - Analysts are optimistic about HRMY's earnings prospects, as indicated by a positive trend in earnings estimate revisions; the Zacks Consensus Estimate for the current year has increased by 7.4% with no negative revisions [11][12] - HRMY holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, which supports the stock's potential upside [13] Analyst Behavior and Price Target Reliability - Analysts often set overly optimistic price targets due to business incentives, which can lead to inflated estimates; thus, investors should approach price targets with skepticism [8][10] - Despite the skepticism surrounding price targets, the direction implied by them may still provide a useful guide for potential price movements [14]

Core Viewpoint - TTM Technologies (TTMI) shows potential for significant upside, with a mean price target of $118.5 indicating a 26.4% increase from the current price of $93.77 [1] Price Targets - The average price target ranges from a low of $108.00 to a high of $126.00, with a standard deviation of $8.58, suggesting a consensus among analysts [2] - The lowest estimate indicates a 15.2% increase, while the highest suggests a 34.4% upside [2] Analyst Consensus and Earnings Estimates - Analysts are increasingly optimistic about TTMI's earnings prospects, with a strong agreement in revising EPS estimates higher, which correlates with potential stock price movements [11] - Over the last 30 days, three estimates have been revised upward, leading to a 14.2% increase in the Zacks Consensus Estimate [12] Zacks Rank - TTMI holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13] Price Movement Guidance - While consensus price targets may not be entirely reliable, the direction they imply appears to be a good guide for potential price movements [14]